Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Matrixyl (Palmitoyl Pentapeptide-4) vs Melanotan I (Afamelanotide)
An educational, source-based comparison of Matrixyl (Palmitoyl Pentapeptide-4) and Melanotan I (Afamelanotide) — how each peptide works, what it's researched for, and what to know before going deeper.
Topical matrikine researched for collagen stimulation.
A signal peptide that mimics the procollagen-I fragment, stimulating fibroblasts to produce collagen, elastin, and glycosaminoglycans in topical cosmetic research.
- Dermal collagen synthesis
- Fine lines and skin firmness
- • Well tolerated in topical use.
- • Modest improvements; not equivalent to retinoids.
Selective MC1R agonist FDA-approved for erythropoietic protoporphyria.
A selective melanocortin-1 receptor (MC1R) agonist that stimulates eumelanin production in melanocytes. FDA-approved (Scenesse) as an implant for erythropoietic protoporphyria, a rare light-sensitive disorder.
- Erythropoietic protoporphyria (FDA-approved)
- UV-independent tanning (research)
- Photoprotection in photosensitivity disorders
- • FDA-approved for EPP via implant formulation only.
- • Not approved for cosmetic tanning.
- • Monitoring for new/changing moles recommended.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Matrixyl (Palmitoyl Pentapeptide-4) | Palmitoyl pentapeptide-4 in anti-aging skincare | International Journal of Cosmetic Science | 2005 | Improved wrinkle parameters versus placebo in topical trial. |
| Melanotan I (Afamelanotide) | Afamelanotide for erythropoietic protoporphyria | New England Journal of Medicine | 2015 | Phase 3 trials showed significant pain reduction and sun tolerance. |
Side-effect & safety grid
- Well tolerated in topical use.
- Modest improvements; not equivalent to retinoids.
- FDA-approved for EPP via implant formulation only.
- Not approved for cosmetic tanning.
- Monitoring for new/changing moles recommended.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Matrixyl (Palmitoyl Pentapeptide-4) vs Melanotan I (Afamelanotide) — Key differences
- Class: Matrixyl (Palmitoyl Pentapeptide-4) is classified as Skin · Collagen, while Melanotan I (Afamelanotide) is Pigmentation · Melanocortin.
- Primary research focus: Matrixyl (Palmitoyl Pentapeptide-4) — dermal collagen synthesis; Melanotan I (Afamelanotide) — erythropoietic protoporphyria (fda-approved).
- Tag: Skin vs Skin · Pigmentation.